Peptide stack interaction checker.
Curated reference pages for the most common community stacks. Each page covers the mechanism rationale, the standard protocol most users actually run, the honest read on evidence quality, and the shared risks worth flagging when two compounds touch overlapping pathways.
Not medical advice. Curated v1 covers 8 stacks. New entries ship as community practice consolidates.
Novo Nordisk's next-gen weight-loss combination. Amylin-receptor agonism (cagrilintide) plus GLP-1 agonism (semaglutide) for synergistic gastric-emptying delay + central satiety amplification.
Three-component fat-loss stack. AOD-9604 for direct lipolysis; ipamorelin + CJC-1295 for endogenous GH pulses driving lipid oxidation. Common in body-composition protocols.
Common community pairing. Tirzepatide drives caloric deficit; BPC-157 supports gut tolerance + tissue repair through the muscle loss + activity changes that come with rapid weight loss.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.